Vertex Pharmaceuticals Incorporated

What does Vertex Pharmaceuticals own?
Vertex owns seven marketed medicines: CF therapies Kalydeco, Orkambi, Symdeko, Trikafta/Kaftrio, and Alyftrek, plus Casgevy (co-owned profit share with CRISPR Therapeutics) and Journavx. Its pipeline includes povetacicept, zimislecel, and inaxaplin. It absorbed Semma, ViaCyte, and Alpine Immune Sciences rather than holding them as separate companies.

Is Vertex publicly traded?
Yes. It trades on NASDAQ under ticker VRTX and is a member of the S&P 500 and NASDAQ-100. Shares have been public since a 1991 IPO.

When was Vertex founded?
Vertex was founded in 1989 in Cambridge, Massachusetts. It moved its headquarters to Boston's Seaport District in 2014.

Who founded Vertex?
Joshua Boger, a former senior scientist at Merck, founded the company with venture capitalist Kevin Kinsella to pursue rational drug design. Reshma Kewalramani is the current president and CEO.

What is Vertex's market position?
Vertex holds an effective monopoly in cystic fibrosis modulators, with medicines used by about 75% of the addressable patient population across 60-plus reimbursed countries. It is among the most valuable biotechnology companies by market capitalization.

Does Vertex own Casgevy?
Vertex co-developed Casgevy with CRISPR Therapeutics and leads commercialization under a profit-sharing agreement, taking 60% of economics. It is not the sole owner of the product.

Joshua Boger left Merck's research leadership in 1989 to found Vertex in Cambridge, Massachusetts, with venture capitalist Kevin Kinsella. The founding premise was rational drug design: engineer molecules against known disease targets instead of relying on trial-and-error screening. The company went public on NASDAQ in 1991, years before it had a product.

Early products were modest. The HIV protease inhibitor Agenerase reached market in 1999 but was eclipsed by rivals and later sold. The first real commercial hit was Incivek, a hepatitis C drug approved in 2011 that generated more than $1 billion in its first year, then collapsed almost as fast when better antivirals arrived.

The CF program, running since 1998 in partnership with the Cystic Fibrosis Foundation, defined the company. Kalydeco, approved in 2012, was the first drug to treat the underlying protein defect rather than symptoms, initially for about 4% of patients with specific mutations. Orkambi (2015) and Symdeko (2018) widened coverage incrementally. Trikafta, approved in October 2019, covered roughly 90% of patients and became one of the fastest drugs in history to reach blockbuster scale, generating $10.3 billion in FY2025 alone.

Parallel bets broadened the base. The 2015 collaboration with CRISPR Therapeutics produced Casgevy, which won UK approval in November 2023 and FDA approval in December 2023, becoming the first CRISPR-based medicine approved anywhere. Semma Therapeutics ($950 million, 2019) and ViaCyte ($320 million, 2022) established the type 1 diabetes cell therapy program now called zimislecel. The April 2024 acquisition of Alpine Immune Sciences for approximately $4.9 billion brought povetacicept, a kidney disease drug that became the company's lead pipeline asset.

Two launches followed in rapid succession: Alyftrek, a once-daily next-generation CF triple combination, approved December 2024, and Journavx, a non-opioid NaV1.8 pain inhibitor approved January 30, 2025. FY2025 revenue reached $12.0 billion, up 9%, and Q3 2026 revenue of $3.44 billion grew 11.8% year over year.

Vertex publishes corporate responsibility reporting covering clinical trial ethics, access programs, and environmental footprint. Its most consequential ethics question is pricing. CF medicines carry list prices near $300,000 per year in the United States, and the company has defended pricing as necessary to fund high-risk rare disease research. Critics, including UK lawmakers during the 2020 Kaftrio reimbursement fight, argue that publicly funded research underwrote parts of the science.

The company operates patient assistance and compassionate use programs and has reached reimbursement agreements covering more than 60 countries, though access remains incomplete in lower-income markets. Casgevy raises a separate ethical dimension as a therapy costing roughly $2.2 million per patient.

• Prix Galien USA (2020): Best biotechnology product for Trikafta, among the most prestigious awards in pharmaceuticals.
• Fortune Most Admired Companies: Regularly ranked among the most admired pharmaceutical companies.
• Time Best Inventions: Casgevy and Journavx were each named to Time's annual innovations lists following their approvals.
• FDA Breakthrough Designations: Multiple programs, including povetacicept and zimislecel, hold breakthrough or RMAT status.

Pricing is the company's standing controversy. The list price of Trikafta drew congressional attention, and in 2020 the UK's National Health Service initially balked at reimbursement for Kaftrio before reaching a confidential pricing deal after months of public dispute. Patient groups have criticized slow access in smaller markets, particularly for children awaiting label expansions.

Patent strategy has also drawn scrutiny. Critics argue Vertex has layered patents to extend exclusivity across the CF franchise, a practice common in the industry but politically sensitive given the franchise's monopoly position and the drugs' origins partly in charity-funded research.

In 2025 and 2026, scrutiny shifted to commercialization pace: Casgevy's slow patient throughput, only 64 infusions in 2025 against 147 cell collections, highlighted the gap between scientific milestone and real-world delivery, and Journavx prescriptions, while ahead of plan, face questions about payer breadth and use beyond the approved acute pain setting.